Skip to content

Study · Case report or series · n = 1 · 2025

1 result

Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?

Yassin Alsabbagh A, Bhujel N, Singh RP

International journal of oral and maxillofacial surgery9 Apr 2025Cited by 1 (Europe PMC)

PMID40210573 (opens in a new tab)DOI10.1016/j.ijom.2025.03.014 (opens in a new tab)PepBankPUB-40210573
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 22-year-old woman developed a mass in the anterior maxilla, confirmed as mucosal malignant melanoma, after using Melanotan II nasal spray; a causal link is not shown.

    In plain wordsOne young woman who used Melanotan II nasal spray developed a mouth melanoma. This single case does not show that the spray caused it.

    Peptide
    Melanotan II
    Outcome
    Not applicableOral mucosal malignant melanoma after Melanotan II nasal spray
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported.
    2 context sentences
    Summary · context
    Histological analysis confirmed the diagnosis of a mucosal malignant melanoma.
    Summary · context
    The patient had used the nasal spray for tanning purposes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.